Showing 1 - 2 results of 2 for search 'Christopher P. Cannon', query time: 0.01s Refine Results
  1. 1
    Lower On‐Treatment Low‐Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials

    Lower On‐Treatment Low‐Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials by Antonio J. Vallejo‐Vaz, Henry N. Ginsberg, Michael H. Davidson, Robert H. Eckel, Christopher P. Cannon, L. Veronica Lee, Laurence Bessac, Robert Pordy, Alexia Letierce, Kausik K. Ray

    Published 2018-09-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial

    Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonis... by David Z.I. Cherney, Robert Frederich, Richard E. Pratley, Francesco Cosentino, Samuel Dagogo-Jack, Annpey Pong, Ira Gantz, Nilo B. Cater, James P. Mancuso, Urszula Masiukiewicz, Christopher P. Cannon

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: